Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Leukemia & Lymphoma
|
October 14, 2015
Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia
Salih Subari, Mrinal Patnaik, Dima Alfakara, et al.
British Journal of Haematology
|
June 17, 2015
Concurrent activating KIT mutations in systemic mastocytosis
Terra Lasho, Christy Finke, Darci Zblewski, et al.
Leukemia Research
|
September 28, 2015
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities
Mehrdad Hefazi, Mustaqeem Siddiqui, Mrinal Patnaik, et al.
Leukemia & Lymphoma
|
February 22, 2018
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience
Aref Al-Kali, Ahmed Kamel Abou Hussein, Mrinal Patnaik, et al.
Leukemia Research
|
October 11, 2016
Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience
Rama Nanah, Darci Zblewski, Mrinal S Patnaik, et al.
Mayo Clinic Proceedings
|
August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013
Aref Al-Kali, Darci Zblewski, James M Foran, et al.
American Journal of Hematology
|
April 10, 2019
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Tucker Coston, Prateek Pophali, Rangit Vallapureddy, et al.
British Journal of Haematology
|
March 18, 2020
Characteristics of patients with myelodysplastic syndrome with balanced translocations
Maansi Joshi, Patricia Greipp, Colleen Ball, et al.
Blood
|
April 16, 2020
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M Patnaik, David A Sallman, Abhishek A Mangaonkar, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Leukemia & Lymphoma
|
October 14, 2015
Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia
Salih Subari, Mrinal Patnaik, Dima Alfakara, et al.
British Journal of Haematology
|
June 17, 2015
Concurrent activating KIT mutations in systemic mastocytosis
Terra Lasho, Christy Finke, Darci Zblewski, et al.
Leukemia Research
|
September 28, 2015
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities
Mehrdad Hefazi, Mustaqeem Siddiqui, Mrinal Patnaik, et al.
Leukemia & Lymphoma
|
February 22, 2018
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience
Aref Al-Kali, Ahmed Kamel Abou Hussein, Mrinal Patnaik, et al.
Leukemia Research
|
October 11, 2016
Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience
Rama Nanah, Darci Zblewski, Mrinal S Patnaik, et al.
Mayo Clinic Proceedings
|
August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013
Aref Al-Kali, Darci Zblewski, James M Foran, et al.
American Journal of Hematology
|
April 10, 2019
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Tucker Coston, Prateek Pophali, Rangit Vallapureddy, et al.
British Journal of Haematology
|
March 18, 2020
Characteristics of patients with myelodysplastic syndrome with balanced translocations
Maansi Joshi, Patricia Greipp, Colleen Ball, et al.
Blood
|
April 16, 2020
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M Patnaik, David A Sallman, Abhishek A Mangaonkar, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Page
of 2